IMC gp100

Drug Profile

IMC gp100

Alternative Names: IMCgp100; ImmTAC-gp100; Monoclonal T cell receptor anti-CD3 scFv fusion protein (IMCgp100)

Latest Information Update: 07 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Immunocore
  • Developer Immunocore; MedImmune
  • Class Cancer vaccines; Proteins
  • Mechanism of Action CD3 antigen inhibitors; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Uveal melanoma
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Malignant melanoma; Uveal melanoma

Most Recent Events

  • 04 Jun 2018 Interim adverse events and efficacy data from a phase I trial in Uveal melanoma released by Immunocore
  • 11 Dec 2017 IMC gp100 receives Promising Innovative Medicine designation by the Medicines and Healthcare Products Regulatory Agency for Uveal melanoma (Metstatic disease) in United Kingdom
  • 13 Nov 2017 Interim pharmacodynamics and efficacy data from a phase I trial in Uveal melanoma released by Immunocore (NCT02570308)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top